Keybanc analyst Thomas Blakey maintains Five9 (NASDAQ:FIVN) with a Overweight and raises the price target from $86 to $94.
Numinus Wellness Continues Tight Expense Management With Strategic Reviews Underway
Psychedelics mental healthcare company Numinus Wellness (OTCQX: NUMIF) posted its financial results for the three months ended Nov. 30, 2023.
Q1 numbers show: